PainChek Ltd
ASX:PCK
Intrinsic Value
PainChek Ltd. engages in the development and commercialisation of mobile medical device applications. [ Read More ]
The intrinsic value of one PCK stock under the Base Case scenario is 0.004 AUD. Compared to the current market price of 0.03 AUD, PainChek Ltd is Overvalued by 87%.
Valuation Backtest
PainChek Ltd
Run backtest to discover the historical profit from buying and selling PCK stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
PainChek Ltd
Current Assets | 3.7m |
Cash & Short-Term Investments | 2m |
Receivables | 1.6m |
Other Current Assets | 131.1k |
Non-Current Assets | 23.6k |
PP&E | 23.6k |
Current Liabilities | 2.5m |
Accounts Payable | 2.2m |
Other Current Liabilities | 281.3k |
Earnings Waterfall
PainChek Ltd
Revenue
|
2.5m
AUD
|
Cost of Revenue
|
-1.5m
AUD
|
Gross Profit
|
962.9k
AUD
|
Operating Expenses
|
-8.7m
AUD
|
Operating Income
|
-7.8m
AUD
|
Other Expenses
|
-10
AUD
|
Net Income
|
-7.8m
AUD
|
Free Cash Flow Analysis
PainChek Ltd
PCK Profitability Score
Profitability Due Diligence
PainChek Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
PainChek Ltd's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
PCK Solvency Score
Solvency Due Diligence
PainChek Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
PainChek Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PCK Price Targets Summary
PainChek Ltd
According to Wall Street analysts, the average 1-year price target for PCK is 0.08 AUD .
Shareholder Return
PCK Price
PainChek Ltd
Average Annual Return | 82.5% |
Standard Deviation of Annual Returns | 251.14% |
Max Drawdown | -93% |
Market Capitalization | 49.1m AUD |
Shares Outstanding | 1 635 830 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
PainChek Ltd. engages in the development and commercialisation of mobile medical device applications. The company is headquartered in Sydney, New South Wales. The company went IPO on 2012-05-01. The Company’s principal activities are development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. Its Paincheck is an Adult and Infant pain assessment applications. Its PainChek technology uses cameras in smartphones and tablets to capture a brief video of the person, which is analyzed in real time using facial recognition software to detect the presence of facial micro-expressions that are indicative of the presence of pain. Its Paincheck uses artificial intelligence (AI) to automatically assess the micro-facial features of pain. Its PainChek technology has multiple regulatory clearances, including TGA (Australia) and CE Mark (Europe) for use as a class 1 medical device to assess pain in people who are unable to reliably verbalize, such people with dementia.
Contact
IPO
Employees
Officers
The intrinsic value of one PCK stock under the Base Case scenario is 0.004 AUD.
Compared to the current market price of 0.03 AUD, PainChek Ltd is Overvalued by 87%.